NEW YORK, Nov 30 (Reuters) – Gilead Sciences Inc
has begun marketing its HIV treatment Truvada in a way thousands
of consumers already use it – to prevent infection with the
virus that causes AIDS.
The post Switching course, Gilead markets HIV drug for prevention appeared first on NASDAQ.